AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).
The US pharmaceutical giant AbbVie and Danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.
US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.
AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio. The takeover was announced in December 2023.
AbbVie has acquired Celsius Therapeutics, a privately held biotechnology company developing new therapies inflammatory diseases, for $250 million in cash. The transaction is subject to certain customary adjustments.
US drugmaker AbbVie and Chinese biopharmaceutical company FutureGen have entered into a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical testing.
Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.
In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
US biopharma AbbVie is to take over Belgian biotech Syndesi Therapeutics, in a move that will expand its neuroscience portfolio. Under the agreed terms, AbbVie will pay Syndesi shareholders an upfront sum of $130 million, with potential additional payments of up to $870 million contingent on achieving certain milestones.
US biopharmas AbbVie and Regenxbio are forming a strategic partnership to develop and commercialize a gene therapy for eye diseases. The transaction is expected to close by the end of 2021, subject to customary closing conditions and regulatory approvals.
US pharma AbbVie has put compatriot Allergan’s women’s health business up for sale. The company is said to be working with Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners. Reuters, which broke the story, said AbbVie’s existing women’s health franchise before picking up Allergan is not part of the sale.
US biopharma AbbVie and compatriot biotech Caribou Biosciences have entered into a multi-year collaboration and license agreement to research and develop chimeric antigen receptor (CAR)-T cell therapeutics.
US biopharma AbbVie has signed a global collaboration agreement with China’s I-Mab to develop and commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies.
